Roche subsidiary Genentech expands breast cancer portfolio with acquisition
Published: Monday, Sep 30th 2024, 09:20
Zurück zu Live Feed
Roche subsidiary Genentech has added new candidates for the treatment of breast cancer to its portfolio with the acquisition of biotech company Regor. In addition to an upfront payment of 850 million US dollars, further milestone payments could be due, the US company announced on Monday.
With the purchase agreement, Genentech acquires Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer. Under the terms of the agreement, Regor will continue the two ongoing Phase I trials until their completion.
The planned transaction is expected to be completed in the fourth quarter of 2024.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic